ArticleUrologic oncology2016
Localizing sites of disease in patients with rising serum prostate-specific antigen up to 1ng/ml following prostatectomy: How much information can conventional imaging provide?
Article in Urologic oncology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 38 citations in OpenAlex.
- Patterns of disease detection using [European journal of nuclear medicine and molecular imaging · 2021Trial
- Article
- Value of a repeatEuropean journal of nuclear medicine and molecular imaging · 2026Article
- Evaluating indeterminate bone lesions and lymph nodes on PSMA-PET: a multidisciplinary consensus algorithm and 1-year implementation results.European radiology · 2026Article
- Article
- Management Impact of Metachronous Oligometastatic Disease Identified onMolecular imaging and biology · 2022Article
- The role of MRI in prostate cancer: current and future directions.Magma (New York, N.Y.) · 2022Review
- [Cancers · 2022Article
- Positivity Rate of [Molecular imaging and biology · 2022Article
- Salvage therapy for prostate cancer after radical prostatectomy.Nature reviews. Urology · 2021Review
- Quantification of Metastatic Prostate Cancer Whole-Body Tumor Burden withJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2021Article
- Seek and Find: Current Prospective Evidence for Prostate-specific Membrane Antigen Imaging to Detect Recurrent Prostate Cancer.European urology focus · 2021Review
- Article
- Early lesion detection withEuropean journal of nuclear medicine and molecular imaging · 2019Article
- Prospective comparison of whole-body MRI andEuropean journal of nuclear medicine and molecular imaging · 2019Article
- Contribution of Radiology to Staging of Prostate Cancer.Seminars in nuclear medicine · 2019Review
- Recurrent prostate cancer after radical prostatectomy: restaging performance of 18F-choline hybrid PET/MRI.Medical oncology (Northwood, London, England) · 2019Article
- Detection Efficacy ofJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2019Article
- Prostate cancer in 2017: Advances in imaging.Nature reviews. Urology · 2018Review
- Detection level and pattern of positive lesions using PSMA PET/CT for staging prior to radiation therapy.Radiation oncology (London, England) · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 1 institution in 1 country.
Funding
Abstract
purposeAccurate identification of the source of a detectable serum prostate-specific antigen (PSA) in the postprostatectomy setting is a major challenge among the urologic community. The aim of this study was to assess positivity rates of imaging examinations performed in patients with early PSA rise after prostatectomy and to summarize the management strategies adopted in this clinical scenario.
methodsInstitutional Review Board-approved retrospective study of 142 postprostatectomy patients with PSA rise up to 1ng/ml who underwent evaluation with combination of multiparametric pelvic magnetic resonance imaging (MRI)±whole-body or bone MRI, bone scintigraphy, computed tomography (CT) chest-abdomen-pelvis,
resultsPelvic MRI was positive in 15/142 (11%) patients (14 patients with local recurrence in the surgical bed and 1 patient with pelvic osseous metastases). Of these 15, 10 patients underwent additional imaging examinations; none revealed positive findings. Of the 127 patients with negative pelvic MRI, 54 (43%) underwent additional imaging examinations; only 1/54 had positive findings (false-positive T8 lesion on bone scintigraphy and FDG-PET/CT; biopsy was negative for cancer). Overall, 12/16 patients with positive imaging findings and 75/126 (60%) patients with negative imaging received treatment (radiation, hormones or chemotherapy).
conclusionThe conventional imaging identified sites of disease, almost always in the form of local recurrence, in a minority of patients with early PSA rise postprostatectomy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.